Mariah Ultramari | Universidade de São Paulo (original) (raw)
Uploads
Papers by Mariah Ultramari
Deleted Journal, 2024
digital) is published monthly by MultiMedia Healthcare, LLC., 2 Commerce Drive Cranbury, NJ 08512... more digital) is published monthly by MultiMedia Healthcare, LLC., 2 Commerce Drive Cranbury, NJ 08512, and is distributed free of charge to users and specifiers of chromatographic equipment in the United States and Canada. LCGC is available on a paid subscription basis to nonqualified readers in the United States and its possessions at the rate of: 1 year (13 issues
Journal of Pharmaceutical Sciences
Revista Brasileira de Toxicologia, 2009
Brazilian Journal of Pharmaceutical Sciences, 2011
A nuclear magnetic resonance (1H NMR) method for the determination of b-N-methylamino-L-alanine (... more A nuclear magnetic resonance (1H NMR) method for the determination of b-N-methylamino-L-alanine (L-BMAA) in environmental aqueous samples was developed and validated. L-BMAA is a neurotoxic modified amino acid that can be produced by cyanobacteria in aqueous environments. This toxin was extracted from samples by means of solid-phase extraction (SPE) and identified and quantified by 1H NMR without further derivatization steps. The lower limit of quantification (LLOQ) was 5 mg/mL. Good inter and intra-assay precision was also observed (relative standard deviation <8.5%) with the use of 4-nitro-DLphenylalanine as an internal standard (IS). This method of 1H NMR analysis is not time consuming and can be readily utilized to monitor L-BMAA and confirm its presence in environmental and biological samples. 2008 Elsevier Ltd. All rights reserved.
Journal of the Brazilian Chemical Society, 2019
Currently, the pharmaceutical industry devotes great attention to drug degradation products becau... more Currently, the pharmaceutical industry devotes great attention to drug degradation products because these compounds can offer risks to patients. A previous degradation study of betahistine (N-α-methyl-2-pyridylethylamine) conducted under different stress conditions detected three main impurities named A, B and C. Degradation products were analyzed by high-resolution mass spectrometry in electrospray source and time of flight analyzer (ESI-TOF) and nuclear magnetic resonance (NMR). Impurity mutagenicity was evaluated by Derek Nexus and Sarah Nexus softwares. Liquid chromatography hyphenate with tandem mass spectrometry (LC-MS/MS) analysis of the betahistine forced degradation sample indicated the presence of a new impurity, which was named impurity C1. 2D NMR experiments allowed the complete structural characterization of the new entity. The active pharmaceutical ingredient and degradation impurities were classified as inactive in the in silico mutagenic studies. Systematic investigation of a forced degradation sample led to the characterization of a new betahistine impurity. The in silico mutagenicity study of the betahistine degradation impurities may be useful in the risk assessment of the drug products.
Em julho de 2008, a ANVISA publicou um informe técnico esclarecendo um item importante da RE nº 1... more Em julho de 2008, a ANVISA publicou um informe técnico esclarecendo um item importante da RE nº 1 (2005), que trata sobre os estudos de estabilidade de medicamentos. Este documento originou uma nova RDC de nº 58, publicada em dezembro de 2013, a qual estabelece limites para produtos de degradação em medicamentos. O objetivo do presente trabalho foi avaliar o comportamento do antineoplástico cloridrato de doxorrubicina frente a condições de decomposição (hidrólise ácida, básica, oxidação, temperatura e fotólise), a fim de se determinar suas principais vias de degradação e também elucidar as estruturas de seus principais produtos de degradação. Para isso foi desenvolvido e validado um método indicativo de estabilidade por HPLC-DAD-MS, o qual utiliza como fase estacionária uma coluna Luna C18(2) (150 mm x 3,0 mm, µm) com gradiente de fase móvel de tampão formiato de amônio 5 mmoles.L-1 pH 3 e metanol e fluxo de 0,3 mL.min-1. Ao longo do estudo foram encontrados diversos produtos de deg...
Toxicon, 2009
A nuclear magnetic resonance ( 1 H NMR) method for the determination of b-N-methylamino-L-alanine... more A nuclear magnetic resonance ( 1 H NMR) method for the determination of b-N-methylamino-L-alanine (L-BMAA) in environmental aqueous samples was developed and validated. L-BMAA is a neurotoxic modified amino acid that can be produced by cyanobacteria in aqueous environments. This toxin was extracted from samples by means of solid-phase extraction (SPE) and identified and quantified by 1 H NMR without further derivatization steps. The lower limit of quantification (LLOQ) was 5 mg/mL. Good inter and intra-assay precision was also observed (relative standard deviation <8.5%) with the use of 4-nitro-DLphenylalanine as an internal standard (IS). This method of 1 H NMR analysis is not time consuming and can be readily utilized to monitor L-BMAA and confirm its presence in environmental and biological samples.
Deleted Journal, 2024
digital) is published monthly by MultiMedia Healthcare, LLC., 2 Commerce Drive Cranbury, NJ 08512... more digital) is published monthly by MultiMedia Healthcare, LLC., 2 Commerce Drive Cranbury, NJ 08512, and is distributed free of charge to users and specifiers of chromatographic equipment in the United States and Canada. LCGC is available on a paid subscription basis to nonqualified readers in the United States and its possessions at the rate of: 1 year (13 issues
Journal of Pharmaceutical Sciences
Revista Brasileira de Toxicologia, 2009
Brazilian Journal of Pharmaceutical Sciences, 2011
A nuclear magnetic resonance (1H NMR) method for the determination of b-N-methylamino-L-alanine (... more A nuclear magnetic resonance (1H NMR) method for the determination of b-N-methylamino-L-alanine (L-BMAA) in environmental aqueous samples was developed and validated. L-BMAA is a neurotoxic modified amino acid that can be produced by cyanobacteria in aqueous environments. This toxin was extracted from samples by means of solid-phase extraction (SPE) and identified and quantified by 1H NMR without further derivatization steps. The lower limit of quantification (LLOQ) was 5 mg/mL. Good inter and intra-assay precision was also observed (relative standard deviation <8.5%) with the use of 4-nitro-DLphenylalanine as an internal standard (IS). This method of 1H NMR analysis is not time consuming and can be readily utilized to monitor L-BMAA and confirm its presence in environmental and biological samples. 2008 Elsevier Ltd. All rights reserved.
Journal of the Brazilian Chemical Society, 2019
Currently, the pharmaceutical industry devotes great attention to drug degradation products becau... more Currently, the pharmaceutical industry devotes great attention to drug degradation products because these compounds can offer risks to patients. A previous degradation study of betahistine (N-α-methyl-2-pyridylethylamine) conducted under different stress conditions detected three main impurities named A, B and C. Degradation products were analyzed by high-resolution mass spectrometry in electrospray source and time of flight analyzer (ESI-TOF) and nuclear magnetic resonance (NMR). Impurity mutagenicity was evaluated by Derek Nexus and Sarah Nexus softwares. Liquid chromatography hyphenate with tandem mass spectrometry (LC-MS/MS) analysis of the betahistine forced degradation sample indicated the presence of a new impurity, which was named impurity C1. 2D NMR experiments allowed the complete structural characterization of the new entity. The active pharmaceutical ingredient and degradation impurities were classified as inactive in the in silico mutagenic studies. Systematic investigation of a forced degradation sample led to the characterization of a new betahistine impurity. The in silico mutagenicity study of the betahistine degradation impurities may be useful in the risk assessment of the drug products.
Em julho de 2008, a ANVISA publicou um informe técnico esclarecendo um item importante da RE nº 1... more Em julho de 2008, a ANVISA publicou um informe técnico esclarecendo um item importante da RE nº 1 (2005), que trata sobre os estudos de estabilidade de medicamentos. Este documento originou uma nova RDC de nº 58, publicada em dezembro de 2013, a qual estabelece limites para produtos de degradação em medicamentos. O objetivo do presente trabalho foi avaliar o comportamento do antineoplástico cloridrato de doxorrubicina frente a condições de decomposição (hidrólise ácida, básica, oxidação, temperatura e fotólise), a fim de se determinar suas principais vias de degradação e também elucidar as estruturas de seus principais produtos de degradação. Para isso foi desenvolvido e validado um método indicativo de estabilidade por HPLC-DAD-MS, o qual utiliza como fase estacionária uma coluna Luna C18(2) (150 mm x 3,0 mm, µm) com gradiente de fase móvel de tampão formiato de amônio 5 mmoles.L-1 pH 3 e metanol e fluxo de 0,3 mL.min-1. Ao longo do estudo foram encontrados diversos produtos de deg...
Toxicon, 2009
A nuclear magnetic resonance ( 1 H NMR) method for the determination of b-N-methylamino-L-alanine... more A nuclear magnetic resonance ( 1 H NMR) method for the determination of b-N-methylamino-L-alanine (L-BMAA) in environmental aqueous samples was developed and validated. L-BMAA is a neurotoxic modified amino acid that can be produced by cyanobacteria in aqueous environments. This toxin was extracted from samples by means of solid-phase extraction (SPE) and identified and quantified by 1 H NMR without further derivatization steps. The lower limit of quantification (LLOQ) was 5 mg/mL. Good inter and intra-assay precision was also observed (relative standard deviation <8.5%) with the use of 4-nitro-DLphenylalanine as an internal standard (IS). This method of 1 H NMR analysis is not time consuming and can be readily utilized to monitor L-BMAA and confirm its presence in environmental and biological samples.